What is Ultromics?
Founded as a spin-out from the University of Oxford, Ultromics is fundamentally redefining the standard of care in cardiology. The company's flagship EchoGo platform utilizes proprietary AI algorithms to analyze standard echocardiographic images, enabling clinicians to identify complex heart conditions with unprecedented precision. By integrating seamlessly into existing clinical workflows, Ultromics addresses the diagnostic gap in cardiovascular medicine, effectively reducing the burden on healthcare systems while improving patient outcomes. Its strategic partnerships with institutions like the Mayo Clinic and the NHS highlight its commitment to evidence-based innovation and clinical validation.
How much funding has Ultromics raised?
Ultromics has raised a total of $100.8M across 4 funding rounds:
Angel/Seed
$2.8M
Series A
$10M
Series B
$33M
Series C
$55M
Angel/Seed (2017): $2.8M with participation from Oxford Sciences Enterprises
Series A (2018): $10M, investors not publicly disclosed
Series B (2021): $33M supported by GV, The Blue Venture Fund, and Optum Ventures
Series C (2025): $55M featuring Oxford University, Oxford Sciences Enterprises, Allegis Capital, Lightrock, Google, Blue Ventures, and The University of Chicago
Key Investors in Ultromics
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent, billion-pound investment company created in 2015 to found, fund and build transformational businesses via the company's unique partnership with the University of Oxford, the worlds #1 research university.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
Optum Ventures
Optum Ventures was created to make health care better for everyone, investing in early-stage companies that are poised to disrupt the status quo in the medical industry.
What's next for Ultromics?
With this latest infusion of capital, Ultromics is well-positioned to accelerate its global commercialization strategy and expand its AI diagnostic suite. The company is expected to focus on scaling its enterprise-level operations, deepening its integration with major U.S. healthcare systems, and potentially exploring new therapeutic areas within cardiovascular health. As the firm transitions from a research-heavy startup to a mature market player, the focus will likely shift toward long-term sustainability, regulatory expansion, and the continued refinement of its predictive analytics to meet the growing demand for automated, high-accuracy diagnostic tools in the global healthcare market.
See full Ultromics company page
